In an adult undergoing alcohol withdrawal after chronic heavy drinking who presents with red‑tinged urine, mild anemia, low creatinine, mild hyperbilirubinemia, elevated alkaline phosphatase, markedly elevated aspartate aminotransferase (AST) with an AST/ALT ratio >2 and elevated alanine aminotransferase (ALT), what is the most likely diagnosis and what initial management steps should be taken?

Diagnosis: Alcohol-Associated Hepatitis (Alcoholic Hepatitis)

This patient most likely has alcohol-associated hepatitis (AH) with concurrent hemolysis or myoglobinuria causing the red-tinged urine, given the characteristic AST/ALT ratio >2, elevated transaminases, hyperbilirubinemia, and context of heavy alcohol withdrawal. 1

Clinical Presentation Analysis

The laboratory pattern is highly characteristic of alcohol-associated liver disease:

• AST 224 with ALT 102 yields an AST/ALT ratio of 2.2, which strongly suggests alcoholic liver disease rather than other etiologies 1, 2, 3
• An AST/ALT ratio >2 is strongly suggestive of alcoholic liver disease, while ratios <1 suggest nonalcoholic steatohepatitis 3
• Both transaminases are elevated but AST rarely exceeds 300 IU/mL in AH, and ALT is typically lower than AST 1
• Hyperbilirubinemia (1.6 mg/dL) with elevated alkaline phosphatase (149) indicates cholestatic injury pattern overlapping with hepatocellular injury 1

The red-tinged urine in this context likely represents:

• Hemolysis (common in severe alcohol-associated liver disease with anemia present: HGB 11.0, HCT 33.3) 2
• Myoglobinuria from rhabdomyolysis (alcohol withdrawal can cause muscle breakdown) 4
• Less likely hematuria, though coagulopathy from liver disease increases bleeding risk 1

The low creatinine (0.58) is paradoxical but explained by decreased muscle mass and malnutrition common in chronic alcohol use disorder, masking potential renal dysfunction 5

Diagnostic Criteria for Alcohol-Associated Hepatitis

Probable AH can be diagnosed clinically without biopsy when the following are present 1:

• Recent onset or worsening jaundice (bilirubin >50 μmol/L or ~3 mg/dL for definite AH, though this patient has 1.6)
• Heavy alcohol use (typically >80 g/day for years) 1
• AST >50 IU/mL but rarely >300 IU/mL 1
• AST/ALT ratio >1.5-2.0 1, 2
• Exclusion of other causes of acute liver injury 1

Liver biopsy (via transjugular route to reduce bleeding risk) is indicated when 1:

• Diagnostic uncertainty exists
• Atypical features are present
• Precise staging is required
• Other diagnoses need exclusion (found in 10-20% of suspected AH cases) 1

Immediate Management Priorities

1. Assess and Manage Alcohol Withdrawal Syndrome

Use CIWA-Ar scoring to stratify withdrawal severity 1:

• Score >8 indicates moderate AWS requiring treatment
• Score ≥15 indicates severe AWS 1

Benzodiazepines are the gold standard for alcohol withdrawal treatment 1:

• Long-acting benzodiazepines (diazepam, chlordiazepoxide) provide better seizure and delirium tremens protection 1
• Short/intermediate-acting benzodiazepines (lorazepam, oxazepam) are safer with hepatic dysfunction 1
• Use symptom-triggered regimens rather than fixed-dose schedules to prevent drug accumulation 1
• Limit use to 10-14 days maximum due to abuse potential 1

2. Investigate the Red-Tinged Urine

Obtain urinalysis with microscopy to differentiate:

• Hemoglobinuria (positive blood on dipstick, no RBCs on microscopy, check hemolysis markers)
• Myoglobinuria (positive blood on dipstick, no RBCs, elevated CK)
• Hematuria (RBCs present on microscopy)

Check additional labs:

• Complete blood count with reticulocyte count (assess hemolysis)
• Creatine kinase (rule out rhabdomyolysis)
• Lactate dehydrogenase, haptoglobin (hemolysis markers)

3. Stratify AH Severity

Calculate prognostic scores to determine disease severity and guide treatment 1, 5:

Maddrey Discriminant Function (mDF) = 4.6 × (PT - control PT) + serum bilirubin (mg/dL) 1:

• mDF ≥32 indicates severe AH with 30-50% mortality at 28 days without treatment 1
• mDF <32 indicates mild/moderate AH with lower but non-zero mortality risk 1

MELD score is the most accurate for stratifying AH severity 5:

• MELD >20 defines severe disease 5
• Calculate using bilirubin, INR, and creatinine 1

Note: This patient's bilirubin of 1.6 mg/dL is relatively mild for classic severe AH (typically >50 μmol/L or ~3 mg/dL), suggesting either early disease or less severe presentation 1

4. Supportive Care and Complication Management

Nutritional support is critical 1, 6, 5:

• Assess for malnutrition (common in ALD)
• Provide thiamine supplementation BEFORE glucose administration to prevent Wernicke's encephalopathy 4
• Consider enteral nutrition supplementation

Screen for infections 6, 5:

• Patients with AH are highly susceptible to bacterial infections
• Maintain low threshold for empiric antibiotics if infection suspected
• Obtain cultures before antibiotics

Monitor for complications 1:

• Hepatic encephalopathy
• Ascites
• Variceal bleeding
• Hepatorenal syndrome
• Acute-on-chronic liver failure

5. Exclude Alternative or Concurrent Diagnoses

Rule out other causes of acute liver injury 1, 7:

• Drug-induced liver injury (acetaminophen level, medication history)
• Viral hepatitis (hepatitis A, B, C serologies)
• Biliary obstruction (right upper quadrant ultrasound)
• Sepsis with cholestasis
• Ischemic hepatitis

6. Address Alcohol Use Disorder

Initiate AUD treatment as abstinence is the most effective strategy to prevent disease progression 1, 5:

• Integrate addiction medicine consultation
• Consider pharmacotherapy (naltrexone, acamprosate, disulfiram) after acute phase
• Baclofen and topiramate show promise for AUD treatment 1
• Arrange multidisciplinary care with hepatology, addiction medicine, and social work 5

Corticosteroid Consideration

Corticosteroids provide short-term survival benefit in severe AH (mDF ≥32 or MELD >20) 1, 5:

• Benefit seen in approximately 50-60% of treated patients at 1 month 5
• Do NOT initiate corticosteroids until active infection is excluded 1
• Requires careful patient selection and monitoring

This patient's current bilirubin (1.6 mg/dL) likely does not meet severity threshold for corticosteroids, but complete assessment with PT/INR is needed to calculate mDF and MELD scores 1

Common Pitfalls

• Overlooking masked renal dysfunction: Low creatinine from sarcopenia can hide acute kidney injury; consider Cystatin C for more accurate GFR assessment 8
• Missing concurrent rhabdomyolysis: Alcohol withdrawal can cause muscle breakdown; always check CK with red/brown urine 4
• Delaying thiamine: Always give thiamine BEFORE glucose to prevent Wernicke's encephalopathy 4
• Starting corticosteroids without excluding infection: Infections are common and corticosteroids are contraindicated until ruled out 1, 5
• Failing to address AUD: Long-term outcomes depend critically on abstinence; integrate addiction treatment from the start 1, 5